Lupin Limited said it has launched generic dasatinib tablets in the United States following U.S. Food and Drug Administration approval of an Abbreviated New Drug Application (ANDA). The company announced the launch on February 2, 2026, saying the product was developed in partnership with Pharmascience Inc. The tablets are offered in six strengths — 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg — and are described as bioequivalent to Bristol-Myers Squibb’s Sprycel® tablets in those same strengths. Lupin also identified subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Reporters and analysts will likely seek clarification from Lupin, Pharmascience and market data providers about manufacturing, commercial rights, and expectations for uptake against the branded product.

Source: The Hindu February 02, 2026 21:04 UTC